Subventions et des contributions :

Titre :

Harnessing the benefits of continuous crystallization to precisely control particular size_x000D_ distribution of active pharmaceutical ingredients

Numéro de l’entente :

EGP

Valeur d'entente :

25 000,00 $

Date d'entente :

10 mai 2017 -

Organisation :

Conseil de recherches en sciences naturelles et en génie du Canada

Location :

Colombie-Britannique, Autre, CA

Numéro de référence :

GC-2017-Q1-00376

Type d'entente :

subvention

Type de rapport :

Subventions et des contributions

Informations supplémentaires :

Subvention ou bourse octroyée s'appliquant à plus d'un exercice financier. (2017-2018 à 2018-2019)

Nom légal du bénéficiaire :

Hein, Jason (The University of British Columbia)

Programme :

Subventions d'engagement partenarial pour les universités

But du programme :

Control of crystallite particle size distribution is essential in the manufacturing of pharmaceutical dosagex000D
forms. In particular, obtaining a narrow size distribution is essential to enable new sustained release technologyx000D
developed by Eupraxia pharmaceuticals. The present workflow presents a significant barrier to scale up andx000D
manufacturing of a novel anti-inflammatory therapy. New techniques designed by the Hein lab, whichx000D
leverages automation and in situ monitoring technology, will help to identify optimal crystallization conditionsx000D
to achieve a narrow and controlled particle size distribution for the active pharmaceutical ingredient. Inx000D
addition, the Hein lab will investigate adapting the optimized crystallization process into a continuousx000D
crystallization workflow, making the final manufacturing stage robust and very efficient.